AbClon

앱클론 · 174900

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$490.1M (₩676.4B)

Overview

AbClon is a South Korean biotech company that develops antibody-based medicines, drugs that use proteins engineered to target and block disease-causing molecules, focused on cancers such as stomach and breast cancer.

Its therapies are designed for use by patients and are developed in partnership with research networks including Swedish scientific groups. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, AbClon operates primarily as an intellectual-property licensing business, having transferred the rights to its lead antibody candidate to a partner for clinical development.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$3.4M

▲ +101.5% YoY

Operating profit · FY2025

−US$12.8M

Loss widened

Net income · FY2025

−US$13M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$2.1M(₩2.9B)	US$1.7M(₩2.3B)	US$3.4M(₩4.7B)
Operating profit	−US$8.4M(−₩11.6B)	−US$11.3M(−₩15.6B)	−US$12.8M(−₩17.6B)
Net income	−US$9.4M(−₩12.9B)	−US$11.8M(−₩16.3B)	−US$13M(−₩17.9B)

Revenue

FY2023US$2.1M
FY2024US$1.7M
FY2025US$3.4M

Operating profit

FY2023−US$8.4M
FY2024−US$11.3M
FY2025−US$12.8M

Net income

FY2023−US$9.4M
FY2024−US$11.8M
FY2025−US$13M

Key ratios (FY2025)

ROE

-29.6%

Debt/Eq

17.1%

Op. margin

-374.1%

Net margin

-379.9%

Rev. YoY

▲ +101.5%

Why it matters

AbClon was co-founded by Korean and Swedish scientist groups, and its research network includes Atlas Therapeutics AB, Affibody AB, and Alligator Bioscience AB in Sweden.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?